v3 Template
E

Ethris

Biotechnology / Healthcare Frankfurt, Germany ~135 employees
Founded
--
Employees (Est.)
~135
9 leaders known
Total Funding
$15.8M
Funding Rounds
2
Last Funding
2025-05-06

About Ethris

Ethris is a pioneer in mRNA technology, focusing on delivering therapeutic proteins through proprietary, clinically validated, non-immunogenic messenger RNA (SNIM® RNA) and lipidoid nanoparticle (SNaP LNP®) platforms. Their mission is to discover, design, and develop innovative therapies and vaccines, particularly for respiratory diseases, with a goal of improving patients' lives through first-in-class treatments like those for uncontrolled asthma.

Products & Services

ETH47:A lead mRNA-based therapeutic candidate targeting large indications such as uncontrolled asthma.
Protein Replacement Therapies:mRNA-based therapies for rare genetic disorders, with an initial focus on primary ciliary dyskinesia (PCD).
Stabilized Non-Immunogenic mRNA (SNIM® RNA) Platform:A technology platform to generate low-immunogenicity, high-potency mRNA molecules with superior production yields.
Stabilized Lipidoid Nanoparticle (SNaP LNP®) Platform:A formulation platform combined with multi-route, multi-cargo delivery systems for advancing mRNA-based programs.

Specialties

mRNA-based therapeutics Respiratory and infectious disease treatments Protein replacement therapies Inhaled mRNA delivery Thermostable mRNA formulations

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Grant
T: -
FT: Grant 		A: 10800000
MR: -
FA: €10 million
FAN: 10800000 		D: 2025-05-06
FD: 2025-05-06 		1 investors
2 RT: Grant with Equity Investment
T: -
FT: Grant with Equity Investment 		A: 5000000
MR: -
FA: $5 million
FAN: 5000000 		D: 2024-06-18
FD: 2024-06-18 		1 investors
Grant Latest
2025-05-06
$10.8M
1 investor (Pro only)
Grant with Equity Investment 2024-06-18
$5.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

C

Carsten Rudolph

Chief Executive Officer

LinkedIn (Pro only)
C

Christian Plank

Chief Technology Officer

LinkedIn (Pro only)
C

Christian Wawrzinek

Chief Corp. Strategy Officer

LinkedIn (Pro only)
T

Thomas Langenickel

Chief Medical Officer

G

Gerd Maass

Chairman of the Board and Member of the CEO Office at Roche Pharmaceuticals

T

Thomas Chalberg

CEO/CSO

View 6 more team members with Pro

Unlock Full Team Directory

Recent News

Ethris Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Website
ethris.com
Industries
Biotechnology / Healthcare
Company Size
~135 employees (est.)
Locations
Frankfurt, Germany
Bend, US

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro